Asset Details
Do you wish to reserve the book?
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
Do you wish to request the book?
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
2017
Overview
In this single-center trial involving term infants with in utero opioid exposure, the use of sublingual buprenorphine resulted in a shorter duration of treatment and length of hospital stay than the use of oral morphine.
The neonatal abstinence syndrome is defined as the occurrence of signs and symptoms of neonatal withdrawal after in utero drug exposure.
1
Among drug exposures, opioids cause severe symptoms, including autonomic instability, tremor, irritability, poor feeding, and loose stool. Measures that improve symptom control include minimization of stimulation, rooming in,
2
breast-feeding,
3
and frequent calorically dense feedings. Approximately two thirds of infants with this condition do not have a response to behavioral approaches and ultimately require pharmacologic therapy for control of symptoms.
4
The administration of an opioid at an appropriate dose for symptom control with subsequent weaning has been identified as an . . .
Publisher
Massachusetts Medical Society
Subject
/ Analgesics, Opioid - adverse effects
/ Analgesics, Opioid - therapeutic use
/ Buprenorphine - adverse effects
/ Buprenorphine - therapeutic use
/ Female
/ Humans
/ Hypnotics and Sedatives - therapeutic use
/ Infants
/ Male
/ Morphine
/ Neonatal abstinence syndrome
/ Neonatal Abstinence Syndrome - drug therapy
/ Neonates
/ Opiate Substitution Treatment
/ Opioids
